Study design. From 1256 men of a Watchful Waiting Cohort, we selected the "Extreme" cases: those who died of prostate cancer or men who lived more than 10 years without signs of progression. We also filtered out some patients based on tumor tissue availability, sample quality or because they were treated. Finally, we randomly divided the patients in a Learning and Validation sets, ensuring that similar proportions of lethals and indolents are present in the two groups.
Sboner et al. BMC Medical Genomics 2010 3:8 doi:10.1186/1755-8794-3-8